Named on one round in the feed.
Since 2026-09-29
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
AnaCardio A clinical-stage biopharmaceutical company developing novel therapies for heart failure | Series B Verified against 1 of 17 sources | $71.0M | 2026-09-29 | [ PART ] |